期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

罗格列酮和吡格列酮对大鼠血浆肌钙蛋白Ⅰ水平的影响

Effect of rosiglitazone and pioglitazone on the level of plasma cardiac troponin Ⅰ in rats
下载PDF
导出
摘要 目的通过比较给予罗格列酮、吡格列酮后大鼠心脏组织形态、血浆肌钙蛋白(cTnI)的变化,研究罗格列酮和吡格列酮对大鼠心脏的毒性作用。方法健康SD雄性大鼠30只,分为5组,每组6只,分别鼻饲给予罗格列酮10、80mg.kg-1.d-1,吡格列酮4、20mg.kg-1.d-1以及等量蒸馏水,连续4周。给药后麻醉动物,剥离大鼠心脏和胫骨,测定心脏重量指数(心脏重量/体重、心脏重量/胫骨长度);心内取血,测定大鼠cTnI含量。结果与空白对照组比较,罗格列酮80mg.kg-1.d-1组大鼠心脏重量、心脏重量/体重、心脏重量/胫骨长度比值均显著增加(P<0.01),血浆cTnI水平显著升高;罗格列酮10mg.kg-1.d-1组的血浆cTnI水平也明显升高,但低于罗格列酮80mg.kg-1.d-1组,心脏重量指数无显著变化。吡格列酮4和20mg.kg-1.d-1组没有观察到显著的心肌形态学和血浆cTnI水平的变化。结论罗格列酮可呈剂量依赖性的引起大鼠心肌损害和心肌肥大,而吡格列酮未见明显的心肌损害。 Objective To investigate the change of cardiac histology and cardiac troponin I level in rats after administration of rosiglitazone and pioglitazone,and compare the toxic effect of rosiglitazone on rat hearts with that of pioglitazone.Methods Thirty healthy male SD rats were divided into 5 groups,with 6 rats in each group.They were administered rosiglitazone 10 and 80 mg·kg-1·d-1,pioglitazone 4 and 20 mg·kg-1·d-1,and distilled water for 4 weeks respectively.The hearts and tibias of rats were separated after the anesthetization to evaluate the heart mass index（heart weight/body weight,heart weight /length of tibias）.The rats were exsanguinated to determine the plasma concentration of cTnI.Results Compared with the blank goup,the heart mass index of rats after the administration of 80 mg·kg-1·d-1 rosiglitazone rose（P0.01）,accompanied by increased cTnI level.No change of heart mass index, but raised cTnI concentration was observed in the rats given rosiglitazone 10 mg·kg-1·d-1,which was lower than that in rats given rosiglitazone 10 mg·kg-1·d-1.No differences were discovered in the rats given pioglitazone（4,20 mg·kg-1·d-1） in terms of heart weight and plasma cTnI concentration. Conclusion Rosiglitazone can induce myocardial damage and cardiocyte hypertrophy in a dose dependent way in rats,which is not observed in rats given pioglitazone.
作者 邓丽菁 毕津莲 李湘斌
机构地区 南华大学附属第一医院药剂科
出处 《中南药学》 CAS 2011年第10期751-754,共4页 Central South Pharmacy
关键词 罗格列酮 吡格列酮 肌钙蛋白Ⅰ rosiglitazone pioglitazone cardiac troponin Ⅰ
分类号 R965.3 [医药卫生—药理学]
  • 相关文献

参考文献14

  • 1Home PD,Pocock SJ,Beck-Nielsen H,et al.Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD):a multicentre,randomised,open-label trial[J].Lancet,2009,373 (9681):2125-2135.
  • 2Nissen SE,Wolski DK.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J].N EnglJ Med,2007,356 (24):2457-2471.
  • 3Hernandez AV,Usmani A,Rajamanickam A,et al.Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus:a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials[J].Am J Cardiovasc Drugs,2011,11 (2):115-128.
  • 4Nesto RW,Bell D,Bonow RO,et al.Thiazolidinedione use,fluid retention,and congestive heart failure:a consensus statement from the Am Heart Association and Am Diabetes Asaociation[J].Circulation,2003,108 (23):2941-2948.
  • 5Bar-Or D,Thomas GW,Bar-Or R.Diagnostic potential of phosphorylated cardiac troponin I as a sensitive,cardiac specific marker for early acute coronary syndrome:Preliminary report[J].Clin Clim Acta,2005,362 (1/2):65-70.
  • 6FDA Drug Safety Communication:Ongoing review of Avandia (rosiglitazone) and cardiovascular safety[OL].2010.http://www.fda.gov/Drugs/DrugSafety/Postmarket Drug Safety Information for Patients and Providers/ucm201418.htmL.
  • 7药品不良反应信息通报(第33期).警惕罗格列酮的心血管系统不良反应[OL].2010.http://www.sda.gov.cn/WS01/CL0078/54813.htmL.
  • 8李立和.急性心肌梗死的实验室诊断研究进展[J].医学综述,2004,10(4):222-224. 被引量：14
  • 9Apple FS,Pearce LA,Smith SW,et al.Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events[J].Clinical Chemistry,2009,55 (5):930-937.
  • 10Wu AH,Lu QA,Todd J,et al.Short-and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay:implications for clinical practice[J].Clinical Chemistry,2009,55 (1):52-58.

二级参考文献43

  • 1Ono K,Han J.The p38 signal transduction pathway:activation and function.Cell Signal,2000,12(1):1-13.
  • 2Passier R,Zeng H,Frey N,Naya FJ,Nicol RL,McKinsey TA,et al.CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.J Clin Invest,2000,105(10):1 395-406.
  • 3Lu J,McKinsey TA,Nicol RL,Olson EN.Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases.Proc Natl Acad Sci U S A,2000,97(8):4 070-075.
  • 4McKinsey TA,Zhang CL,Lu J,Olson EN.Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation.Nature,2000,408(6808):106-111.
  • 5Frey N, Olson EN . Cardiac hypertrophy: the good, the bad, and the ugly.Annu Rev Physiol,2003,65: 45-79.
  • 6van Empel VP.De Windt LJ.Myocyte hypertrophy and apoptosis:a balancing act.Cardiovasc Res,2004,63(3): 487-499.
  • 7Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, et al. Loss of a gp130 2cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress.Cell, 1999, 97 (2): 189-198.
  • 8Marin-Garcia J, Goldenthal MJ. Heart mitochondria signaling pathways:appraisal of an emerging field.J Mol Med,2004 82(9):565-578.
  • 9Kunisada K,Negoro S,Tone E,Funamoto M,Osugi T,Yamada S,etal.Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopsthy.Proc Natl Acad Sci USA,2000,97(1): 315-319.
  • 10Selvetella G, Hirsch E, Notte A,Tarone G,Lembo G. Adaptive and maladaptive hypertrophic pathways:points of convergence and divergence.Cardiovasc Res,2004,63(3): 373-380.

共引文献32

中南药学
2011年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部